Pay in 4 interest-free payments of $6.95 Learn more
Ships within 48 hours · Estimated delivery Sep 9 - Sep 14
Buyer Takeaway: GLP-1 medications have a substantial clinical evidence base
2025 saw a bidding war between Pfizer and Novo Nordisk for Metsera and its portfolio of obesity agents, which was ultimately won by Pfizer for up to $10 billion
adults had already taken GLP-1 at some point and the global market is projected to triple in the next five years, driven by high and rising levels of type-2 diabetes and obesity, aging populations, urbanization and public health initiatives: (2018-2030E) Global pharmaceutical companies dominate todays production: With ~300 clinical trials around the world, research continues into applications to other metabolic disorders, cardiovascular and kidney disease and neurological conditions
CRITICAL INSIGHT: The participants who maintained lean mass through treatment averaged 110g protein daily with resistance training twice weekly
Constipation : Tirzepatide can sometimes cause constipation, which may be uncomfortable if it persists
